Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$86.25
3.324.00%
al cierre: Nov 26, 4:00 PM EST
$86.19
-0.06-0.07%
After hour: 5:21 PM EST
Comments
Loading...
Calificaciones de analistas, precios objetivo, pronóstico
PTC Therapeutics Inc tiene un precio objetivo de consenso de $66.6 basado en las calificaciones de 21 analistas. El máximo es $118, emitido por Cantor Fitzgerald el septiembre 3, 2025. El mínimo es $17, emitido por Citigroup el octubre 27, 2023. Las 3 calificaciones de analistas más recientes fueron publicadas por Barclays, Citigroup y TD Cowen el noviembre 6, 2025, noviembre 5, 2025 y noviembre 5, 2025, respectivamente. Con un precio objetivo promedio de $68.67 entre Barclays, Citigroup y TD Cowen, hay una -20.33% downside implícita para PTC Therapeutics Inc según estas calificaciones más recientes de analistas.
Firmas de analistas que realizan recomendaciones1
Barclays
Citigroup
TD Cowen
RBC Capital
Goldman Sachs
1calculado a partir de las calificaciones de los analistas
Calificaciones de analistas para PTC Therapeutics
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
11/06/2025 | -21.1% | Barclays | $46 → $68 | Maintains | Equal-Weight | |||
11/05/2025 | -12.98% | Citigroup | $50 → $75 | Maintains | Neutral | |||
11/05/2025 | -26.91% | TD Cowen | $50 → $63 | Maintains | Hold | |||
11/05/2025 | -4.86% | RBC Capital | $70 → $82 | Maintains | Outperform | |||
11/05/2025 | -41.99% | Goldman Sachs | $44 → $50 | Maintains | Sell | |||
11/05/2025 | 7.9% | Wells Fargo | $73 → $93 | Maintains | Overweight | |||
10/28/2025 | -10.66% | Jefferies | $63 → $77 | Maintains | Buy | |||
09/03/2025 | 36.91% | Cantor Fitzgerald | $118 → $118 | Reiterates | Overweight → Overweight | |||
08/20/2025 | -15.3% | Wells Fargo | $79 → $73 | Maintains | Overweight | |||
08/20/2025 | -17.62% | Morgan Stanley | $76 → $71 | Maintains | Overweight | |||
08/20/2025 | -11.82% | B of A Securities | $82 → $76 | Maintains | Buy | |||
08/08/2025 | -11.82% | Morgan Stanley | $70 → $76 | Maintains | Overweight | |||
08/08/2025 | -26.91% | RBC Capital | $60 → $63 | Maintains | Outperform | |||
08/08/2025 | -8.34% | Wells Fargo | $78 → $79 | Maintains | Overweight | |||
07/29/2025 | -0.22% | Truist Securities | $80 → $86 | Maintains | Buy | |||
07/29/2025 | -2.54% | B of A Securities | $68 → $84 | Maintains | Buy | |||
07/29/2025 | -46.63% | Barclays | $42 → $46 | Maintains | Equal-Weight | |||
07/29/2025 | -9.5% | Wells Fargo | $74 → $78 | Maintains | Overweight | |||
07/29/2025 | 39.23% | Cantor Fitzgerald | $112 → $120 | Maintains | Overweight | |||
07/29/2025 | -7.18% | UBS | $71 → $80 | Maintains | Buy | |||
07/28/2025 | -41.99% | Citigroup | $40 → $50 | Maintains | Neutral | |||
06/17/2025 | -7.18% | Truist Securities | → $80 | Initiates | → Buy | |||
05/27/2025 | -14.14% | Wells Fargo | $68 → $74 | Maintains | Overweight | |||
05/09/2025 | -21.1% | B of A Securities | $55 → $68 | Upgrade | Neutral → Buy | |||
05/08/2025 | -51.27% | Barclays | $56 → $42 | Maintains | Equal-Weight | |||
05/07/2025 | -23.42% | Baird | $70 → $66 | Maintains | Outperform | |||
05/07/2025 | -32.71% | RBC Capital | $57 → $58 | Maintains | Outperform | |||
05/07/2025 | 29.95% | Cantor Fitzgerald | $113 → $112 | Maintains | Overweight | |||
05/07/2025 | -22.26% | JP Morgan | $75 → $67 | Maintains | Overweight | |||
05/07/2025 | -53.59% | Citigroup | $50 → $40 | Upgrade | Sell → Neutral | |||
04/22/2025 | -24.59% | RBC Capital | $65 → $65 | Reiterates | Outperform → Outperform | |||
03/31/2025 | -12.98% | JP Morgan | $78 → $75 | Maintains | Overweight | |||
03/14/2025 | -9.5% | JP Morgan | $72 → $78 | Maintains | Overweight | |||
03/11/2025 | -36.19% | B of A Securities | $41 → $55 | Upgrade | Underperform → Neutral | |||
03/07/2025 | -36.19% | Scotiabank | → $55 | Initiates | → Sector Perform | |||
03/07/2025 | -18.78% | Morgan Stanley | $67 → $70 | Assumes | → Overweight | |||
02/28/2025 | -16.46% | JP Morgan | $74 → $72 | Maintains | Overweight | |||
02/18/2025 | -26.91% | RBC Capital | $60 → $63 | Maintains | Outperform | |||
02/12/2025 | -47.79% | Citigroup | $32 → $45 | Maintains | Sell | |||
02/03/2025 | 31.11% | Cantor Fitzgerald | $76 → $113 | Maintains | Overweight | |||
01/15/2025 | -11.82% | Cantor Fitzgerald | $80 → $76 | Maintains | Overweight | |||
12/13/2024 | -22.26% | Morgan Stanley | $45 → $67 | Upgrade | Equal-Weight → Overweight | |||
12/04/2024 | -62.87% | Citigroup | $26 → $32 | Maintains | Sell | |||
12/04/2024 | -51.27% | Goldman Sachs | $32 → $42 | Maintains | Sell | |||
12/03/2024 | -17.62% | UBS | $47 → $71 | Maintains | Buy | |||
12/03/2024 | -18.78% | Baird | $52 → $70 | Maintains | Outperform | |||
12/03/2024 | -35.03% | Barclays | $45 → $56 | Maintains | Equal-Weight | |||
11/27/2024 | -39.67% | Baird | $48 → $52 | Maintains | Outperform | |||
11/26/2024 | -21.1% | Wells Fargo | $56 → $68 | Maintains | Overweight | |||
11/19/2024 | -28.07% | JP Morgan | $51 → $62 | Maintains | Overweight | |||
11/14/2024 | -47.79% | Barclays | $43 → $45 | Maintains | Equal-Weight | |||
11/11/2024 | -50.11% | Barclays | $31 → $43 | Maintains | Equal-Weight | |||
11/08/2024 | -44.31% | Baird | $44 → $48 | Maintains | Outperform | |||
10/11/2024 | -47.79% | Morgan Stanley | $32 → $45 | Maintains | Equal-Weight | |||
10/08/2024 | -48.95% | Baird | $44 → $44 | Reiterates | Outperform → Outperform | |||
10/04/2024 | -60.55% | RBC Capital | $32 → $34 | Maintains | Sector Perform | |||
09/20/2024 | -25.75% | Cantor Fitzgerald | $64 → $64 | Reiterates | Overweight → Overweight | |||
09/17/2024 | -25.75% | Cantor Fitzgerald | $64 → $64 | Reiterates | Overweight → Overweight | |||
09/04/2024 | -48.95% | Baird | → $44 | Initiates | → Outperform | |||
08/26/2024 | -45.47% | UBS | → $47 | Upgrade | Neutral → Buy | |||
08/21/2024 | -25.75% | Cantor Fitzgerald | $64 → $64 | Reiterates | Overweight → Overweight | |||
08/09/2024 | -25.75% | Cantor Fitzgerald | $62 → $64 | Maintains | Overweight | |||
08/09/2024 | -64.03% | Barclays | $25 → $31 | Maintains | Equal-Weight | |||
07/16/2024 | -28.07% | Cantor Fitzgerald | $62 → $62 | Reiterates | Overweight → Overweight | |||
07/12/2024 | -62.87% | Morgan Stanley | $30 → $32 | Maintains | Equal-Weight | |||
07/01/2024 | -28.07% | Cantor Fitzgerald | $52 → $62 | Maintains | Overweight | |||
06/21/2024 | -62.87% | B of A Securities | $25 → $32 | Maintains | Underperform | |||
06/20/2024 | -38.51% | JP Morgan | $53 → $53 | Maintains | Overweight | |||
05/28/2024 | -62.87% | Goldman Sachs | $18 → $32 | Maintains | Sell | |||
05/21/2024 | -69.83% | Citigroup | $18 → $26 | Maintains | Sell | |||
05/21/2024 | -38.51% | JP Morgan | $43 → $53 | Maintains | Overweight | |||
05/21/2024 | -62.87% | Goldman Sachs | $18 → $32 | Maintains | Sell | |||
05/20/2024 | -46.63% | Jefferies | $35 → $46 | Maintains | Buy | |||
04/29/2024 | -65.19% | Morgan Stanley | $28 → $30 | Upgrade | Underweight → Equal-Weight | |||
04/12/2024 | -47.79% | Cantor Fitzgerald | $45 → $45 | Reiterates | Overweight → Overweight | |||
03/20/2024 | -59.39% | Jefferies | $33 → $35 | Maintains | Buy | |||
03/08/2024 | -67.51% | RBC Capital | $28 → $28 | Reiterates | Sector Perform → Sector Perform | |||
03/01/2024 | -47.79% | Cantor Fitzgerald | $45 → $45 | Reiterates | Overweight → Overweight | |||
03/01/2024 | -67.51% | RBC Capital | $22 → $28 | Maintains | Sector Perform | |||
03/01/2024 | -65.19% | TD Cowen | $32 → $30 | Maintains | Market Perform | |||
01/26/2024 | -74.47% | RBC Capital | $27 → $22 | Maintains | Sector Perform | |||
01/26/2024 | -47.79% | Cantor Fitzgerald | $51 → $45 | Maintains | Overweight | |||
12/19/2023 | -67.51% | Morgan Stanley | → $28 | Downgrade | Equal-Weight → Underweight | |||
12/18/2023 | -40.83% | Cantor Fitzgerald | $51 → $51 | Reiterates | Overweight → Overweight | |||
12/18/2023 | -79.12% | Goldman Sachs | $20 → $18 | Maintains | Sell | |||
11/20/2023 | -40.83% | Cantor Fitzgerald | → $51 | Reiterates | Overweight → Overweight | |||
10/27/2023 | -67.51% | Morgan Stanley | $31 → $28 | Maintains | Equal-Weight | |||
10/27/2023 | -70.99% | Barclays | $26 → $25 | Maintains | Equal-Weight | |||
10/27/2023 | -80.28% | Citigroup | $29 → $17 | Downgrade | Neutral → Sell | |||
10/06/2023 | -70.99% | Truist Securities | → $25 | Downgrade | Buy → Hold | |||
09/19/2023 | -47.79% | Truist Securities | → $45 | Reiterates | Buy → Buy | |||
09/19/2023 | -73.31% | B of A Securities | $43 → $23 | Maintains | Underperform | |||
09/18/2023 | -47.79% | Truist Securities | $60 → $45 | Maintains | Buy | |||
09/18/2023 | -69.83% | Barclays | $44 → $26 | Maintains | Equal-Weight | |||
09/18/2023 | -64.03% | Morgan Stanley | $47 → $31 | Maintains | Equal-Weight | |||
09/18/2023 | -74.47% | Goldman Sachs | $35 → $22 | Maintains | Sell | |||
09/18/2023 | -69.83% | RBC Capital | $49 → $26 | Maintains | Sector Perform | |||
09/18/2023 | -66.35% | Citigroup | $55 → $29 | Downgrade | Buy → Neutral | |||
09/18/2023 | — | Raymond James | — | Downgrade | Outperform → Underperform | |||
09/15/2023 | — | Raymond James | — | Downgrade | Outperform → Underperform |
PREGUNTAS FRECUENTES
¿Cuál es el precio objetivo de las acciones de PTC Therapeutics (PTCT)?
El último precio objetivo de PTC Therapeutics (NASDAQ:PTCT) fue comunicado por Barclays el noviembre 6, 2025. La firma de analistas fijó un precio objetivo para $68.00 que espera PTCT a fall dentro de 12 meses (un posible -21.10% downside). 47 firmas de analistas han reportado calificaciones en el último año.
¿Cuál es la calificación más reciente de los analistas sobre PTC Therapeutics (PTCT)?
La última calificación de analistas para PTC Therapeutics (NASDAQ:PTCT) fue proporcionada por Barclays, y PTC Therapeutics mantuvo su equal-weight calificación.
¿Cuándo se produjo la última revisión al alza de PTC Therapeutics (PTCT)?
La última revisión al alza de PTC Therapeutics Inc se produjo en mayo 9, 2025, cuando B of A Securities elevó su precio objetivo a $68. B of A Securities anteriormente tenía a neutral para PTC Therapeutics Inc.
¿Cuándo fue la última revisión a la baja de PTC Therapeutics (PTCT)?
La última revisión a la baja de PTC Therapeutics Inc se produjo en diciembre 19, 2023, cuando Morgan Stanley cambió su precio objetivo de N/A a $28 para PTC Therapeutics Inc.
¿Cuándo se publicará o actualizará la próxima calificación de los analistas para PTC Therapeutics (PTCT)?
Los analistas llegan a las calificaciones de acciones después de hacer una investigación exhaustiva, que incluye revisar los estados financieros públicos, hablar con ejecutivos y clientes de PTC Therapeutics, y escuchar las teleconferencias de ganancias. La mayoría de los analistas hacen esto cada tres meses, por lo que deberías recibir 4 calificaciones por empresa al año. La última calificación de PTC Therapeutics se registró el noviembre 6, 2025, por lo que la próxima calificación estará disponible en torno al noviembre 6, 2026.
¿Es correcta la calificación de los analistas sobre PTC Therapeutics (PTCT)?
Aunque las calificaciones son subjetivas y pueden cambiar, la última calificación de PTC Therapeutics (PTCT) fue un mantuvo con un precio objetivo de $46.00 a $68.00. El precio actual al que cotiza PTC Therapeutics (PTCT) es de $86.19, que es out of del rango previsto por el analista.
Explora calificaciones de analistas y precios objetivo sobre todos los valores.